SCAN Health Plan will expand its 2026 Medicare Advantage benefits with $0 copays and higher dental, vision and allowance ...

Rhapsido is the first and only Bruton’s tyrosine kinase (BTK) inhibitor approved for chronic spontaneous urticaria (CSU). The FDA has approved Rhapsido (remibrutinib), an oral treatment for adult ...

Most of the exposure to misinformation about cancer treatment occurs in conversations with family and friends and on social media. Most cancer patients encounter misinformation about treatments, often ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for value-driven solutions.

Pfizer only offered to discount six products through the Most Favored Nation program, and healthcare policy experts suggest the real-world impact remains uncertain.

In a recent trial, verapamil showed a trend toward preserving insulin-producing beta cells in patients with Type 1 diabetes but failed to achieve statistical significance.

Enrollment in Medicare Advantage Special Needs Plans (SNPs) has grown steadily since becoming permanent in 2018, now accounting for 21% of Medicare Advantage enrollees, with recent growth driven by ...

Panelists discuss how maintaining patients on effective single therapies for Crohn’s disease is preferable to switching ...

Novartis said that it is exploring an additional direct-to-employer model to increase access and affordability for cash-paying patients in the United States.

In this conversation with Kristin Begley, chief commercial officer at Capital Rx, we discussed the company’s recent rebrand to Judi Health and how it reflects broader trends in technology-driven, ...

If approved, Awiqli would become the first once-weekly basal insulin available in the United States for adults with Type 2 diabetes.

Panelists discuss how the expanding treatment landscape for Crohn’s disease includes multiple mechanisms of action such as anti-tumor necrosis factor (TNF) agents, anti-integrin agents, interleukin ...